POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk Group

Video
Conference|ASCO Annual Meeting: Hematology

This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.

In this video, Katja Weisel, MD, of the University of Tübingen in Germany, reviews updated results of two phase III trials in relapsed or refractory multiple myeloma that revealed the impact of daratumumab combinations across cytogenetic risk groups.

POLLUX tested daratumumab in combination with lenalidomide plus dexamethasone (DRd) vs lenalidomide plus dexamethasone (Rd). Patients on this trial had a median of 1 prior treatment.

CASTOR tested daratumumab in combination with bortezomib plus dexamethasone (DVd) vs bortezomib plus dexamethasone (Vd). Patients on this trial had a median of 2 prior treatments and 42% of patients had already been treated with lenalidomide.

Weisel presented results of the study (abstract 8006) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

Roman Fabbricatore
March 17th 2025
Article

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

Roman Fabbricatore
March 7th 2025
Article

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.

UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies

Roman Fabbricatore
February 13th 2025
Article

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.